Product Detail
Product NameCD272 Antibody HRP Conjugated
Host SpeciesRabbit
ClonalityPolyclonal
IsotypeIgG
PurificationPurified by Protein A.
ApplicationsWB IHC-P IHC-F ICC
Species ReactivityHu Ms Rt
Immunogen DescKLH conjugated synthetic peptide aa 239-289 289 derived from human B and T-lymphocyte attenuator
Target NameCD272
ConjugateHRP
Excitation EmissionN A
Other NamesBTLA1; CD272; B- and T-lymphocyte attenuator; B- and T-lymphocyte-associated protein; BTLA
Accession NoSwiss-Prot#Q7Z6A9
NCBI Gene ID151888
Uniprot
Q7Z6A9
Gene ID
151888;
Concentration1mg ml
Formulation0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
StorageShipped at 4˚C. Store at -20˚C for one year. Avoid repeated freeze/thaw cycles.
Application Details
WB=1:500-2000 IHC-P=1:50-200 IHC-F=1:50-200 ICC=1:50-200
B and T lymphocyte attenuator (BTLA), an immunoglobulin domain-containing glycoprotein with two immunoreceptor tyrosine-based inhibitory motifs. BTLA is not expressed by naive T cells, but it is induced during activation and remains expressed on T helper type 1 (T(H)1) but not T(H)2 cells. Crosslinking BTLA with antigen receptors induces its tyrosine phosphorylation and association with the Src homology domain 2 (SH2)-containing protein tyrosine phosphatases SHP-1 and SHP-2, and attenuates production of interleukin 2 (IL-2). BTLA-deficient T cells show increased proliferation, and BTLA-deficient mice have increased specific antibody responses and enhanced sensitivity to experimental autoimmune encephalomyelitis. B7x, a peripheral homolog of B7, is a ligand of BTLA. Thus, BTLA is a third inhibitory receptor on T lymphocytes with similarities to cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1).
If you have published an article using product C00354H, please notify us so that we can cite your literature.
15 business days.
